Atezolizumab Combination is Not Superior to Standard of Care for Chemotherapy-Refractory Metastatic Colorectal Cancer


Josep Tabernero, MD, PhD, ESMO president, director, Vall d’Hebron Institute of Oncology, Barcelona, Spain, discusses the results of the phase 3 IMblaze70 trial comparing atezolizumab plus cobimetinib and atezolizumab monotherapy versus standard-of-care regorafenib in chemotherapy-refractory metastatic colorectal cancer, presented by Johanna Bendell, at the 2018 ESMO World Congress on Gastrointestinal Cancer.



Stay in the know.
OncNet Newsletter